Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2014

View Archived Issues

Full year report - 2013 was a successful year for Lundbeck

Technetium Tc 99m trofolastat accurately detects cancer in the prostate gland

Takeda Pharmaceutical advances key programs in third quarter of fiscal 2013

ARADES and ARAFOR trial data reported for ODM-201 in prostate cancer

Protalex reports data from phase Ib trial of PRTX-100 in active rheumatoid arthritis

arGEN-X begins phase Ib study of ARGX-111

GlaxoSmithKline reports discovery of selective androgen receptor modulators

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Merck & Co. discloses new HIV prodrugs

Regeneron Pharmaceuticals and Bayer HealthCare report 2-year data from VISTA-DME trial

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

EMA's Committee for Orphan Medicinal Products issues positive opinion on Arikace

Biogen Idec patent divulges novel S1P modulating agents

Merck & Co. reports development of DPP IV inhibitors for diabetes

Sarepta Therapeutics reports safety data from phase I study of AVI-7288

Study of Repros' Androxal shows sustained effect in men with secondary hypogonadism

Aduro BioTech begins phase IIb ECLIPSE trial in patients with pancreatic cancer

Audion Therapeutics and Lilly to develop hearing loss treatments

Results from preliminary safety study evaluating trebananib plus abiraterone in patients with CRPC

Gilead submits NDA for fixed-dose combination tablet for HCV infection

Lipocine begins dosing in pivotal SOAR study

Oramed submits phase IIa protocol to FDA for oral insulin capsule

Scancell's SCIB-1 receives FDA orphan drug status for metastatic melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...